Developing a high throughput platform for the empirical discovery of molecular glues
Maria Soloveychik
CEO, SyntheX
SyntheX is focused on the empirical discovery of protein interaction modulators using a synthetic biology approach which relies on functional selection. The ToRNeDO platform has been developed to enable molecular glue degrader discovery for novel E3 ligase - neosubstrate pairs. While modality agnostic, ToRNeDO can accommodate small molecule screening as well as discovering peptides that act as functional protein degraders.
Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. SyntheX was founded in 2016 and is based in San Francisco. Maria has obtained her PhD from the department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium, where her work led to the determination of numerous structures and identification of several drug candidates.